HN2010002518A - Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina - Google Patents
Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrinaInfo
- Publication number
- HN2010002518A HN2010002518A HN2010002518A HN2010002518A HN2010002518A HN 2010002518 A HN2010002518 A HN 2010002518A HN 2010002518 A HN2010002518 A HN 2010002518A HN 2010002518 A HN2010002518 A HN 2010002518A HN 2010002518 A HN2010002518 A HN 2010002518A
- Authority
- HN
- Honduras
- Prior art keywords
- cyclodextrine
- vitamin
- pharmaceutical composition
- strontium salt
- strontium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA SAL DE ESTRONCIO, VITAMINA D Y UNA CICLODEXTRINA, ASI COMO A SU UTILIZACION EN EL TRATAMIENTO DE LAS ENFERMEDADES OSEAS Y DE LA ARTROSIS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0905706A FR2953139B1 (fr) | 2009-11-27 | 2009-11-27 | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2010002518A true HN2010002518A (es) | 2012-09-03 |
Family
ID=41719206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2010002518A HN2010002518A (es) | 2009-11-27 | 2010-11-26 | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina |
Country Status (31)
Country | Link |
---|---|
US (1) | US20110130370A1 (es) |
EP (1) | EP2335704A1 (es) |
JP (1) | JP2011111458A (es) |
KR (1) | KR101278935B1 (es) |
CN (1) | CN102078620A (es) |
AP (1) | AP2010005490A0 (es) |
AR (1) | AR079160A1 (es) |
AU (1) | AU2010241527B2 (es) |
BR (1) | BRPI1004685A2 (es) |
CA (1) | CA2723119C (es) |
CL (1) | CL2010001260A1 (es) |
CO (1) | CO6280058A1 (es) |
CU (1) | CU20100230A7 (es) |
EA (1) | EA018460B1 (es) |
EC (1) | ECSP10010622A (es) |
FR (1) | FR2953139B1 (es) |
GE (1) | GEP20135734B (es) |
HN (1) | HN2010002518A (es) |
IL (1) | IL209348A0 (es) |
MA (1) | MA32363B1 (es) |
MX (1) | MX2010012566A (es) |
MY (1) | MY158261A (es) |
NZ (1) | NZ589513A (es) |
PE (1) | PE20110407A1 (es) |
SG (1) | SG171542A1 (es) |
SV (1) | SV2010003744A (es) |
TW (1) | TW201200136A (es) |
UA (1) | UA105766C2 (es) |
UY (1) | UY33039A (es) |
WO (1) | WO2011064474A1 (es) |
ZA (1) | ZA201008230B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1993559T3 (pl) | 2006-02-03 | 2017-01-31 | Opko Renal, Llc | Leczenie niedoboru i deficytu witaminy d z zastosowaniem 25-hydroksywitaminy d2 i 25-hydroksywitaminy d3 |
LT2679228T (lt) | 2006-06-21 | 2018-05-10 | Opko Ireland Global Holdings, Ltd. | Terapija naudojant vitamino d atstatymo agentą ir vitamino d hormoninį pakaitinį agentą |
WO2008134512A1 (en) | 2007-04-25 | 2008-11-06 | Cytochroma Inc. | Oral controlled release compositions comprising vitamin d compound and waxy carrier |
KR101495578B1 (ko) | 2007-04-25 | 2015-02-25 | 사이토크로마 인코포레이티드 | 비타민 d 부족 및 결핍의 치료 방법 |
PT3133070T (pt) | 2009-11-27 | 2019-11-11 | Genzyme Corp | Eliglustat (genz 112638) como inibidor de glicosilceramida-sintase para utilização num método de tratamento de doença de fabry ou de gaucher, o método compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente |
KR102125424B1 (ko) | 2010-03-29 | 2020-06-22 | 사이토크로마 인코포레이티드 | 부갑상선 수준을 낮추기 위한 방법 및 조성물 |
CN102525975B (zh) * | 2011-12-14 | 2013-06-19 | 天津药物研究院药业有限责任公司 | 雷奈酸锶口腔崩解片及其制备方法 |
CN102626420B (zh) * | 2012-04-13 | 2014-06-25 | 深圳大学 | 一种含有锶、钙和维生素d的混合制剂 |
ES2505716T3 (es) * | 2013-01-21 | 2015-09-04 | Galenicum Health S.L. | Composiciones farmacéuticas que comprenden una sal de ácido |
KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 d 방출 제형 |
CN103142623B (zh) * | 2013-03-21 | 2014-04-16 | 青岛正大海尔制药有限公司 | 骨化三醇和雷尼酸锶的混悬颗粒及其制备方法 |
CR20170085A (es) | 2014-08-07 | 2017-04-25 | Opko Ireland Global Holdings Ltd | Terapia adjuntiva con 25-hidroxi vitamina d |
WO2016098904A1 (ja) * | 2014-12-19 | 2016-06-23 | 国立大学法人 長崎大学 | 新規ビスホスホン酸誘導体及びその用途 |
JP7032322B2 (ja) | 2016-03-28 | 2022-03-08 | オプコ アイルランド グローバル ホールディングス リミテッド | ビタミンd治療法 |
US10463636B2 (en) * | 2016-09-30 | 2019-11-05 | Deanna J. Nelson | Pharmaceutical quality strontium L-lactate |
SG10202107237SA (en) * | 2017-04-25 | 2021-08-30 | Buck Inst Res Aging | Formulations for extending lifespan and healthspan |
WO2019004984A2 (en) * | 2017-05-29 | 2019-01-03 | Biofarma Ilac Sanayi Ve Ticaret A.S. | PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL |
CN109276710A (zh) * | 2018-11-23 | 2019-01-29 | 中国医学科学院药用植物研究所海南分所 | 一种增加骨密度的组合物及其制备方法和用途 |
CN112370429A (zh) * | 2019-10-21 | 2021-02-19 | 广州富诺营养科技有限公司 | 一种直压型有机钙维生素d3咀嚼片及其制备方法 |
CN114452259A (zh) * | 2021-07-28 | 2022-05-10 | 安徽旺盛添加剂有限公司 | 一种维生素d微囊钙片及其制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS52130904A (en) * | 1976-04-26 | 1977-11-02 | Teijin Ltd | Stabilization of vitamin d# |
HU177586B (en) * | 1978-12-19 | 1981-11-28 | Chinoin Gyogyszer Es Vegyeszet | New process for preparing stable inclusion complexes of vitamine d with cyclodextrin |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
FR2651497B1 (fr) | 1989-09-01 | 1991-10-25 | Adir | Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
CN1110275A (zh) * | 1994-04-06 | 1995-10-18 | 福建省药品检验所 | 一种维生素D与羟丙基-β-环糊精的包合物 |
FR2749759B1 (fr) | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
JP2003514925A (ja) * | 1999-11-12 | 2003-04-22 | ピサ・アンド・ピサ・エルエルシー | ベータ−シクロデキストリン及び関連化合物の部分メチルエーテルの結晶性混合物 |
WO2001048024A1 (en) * | 1999-12-23 | 2001-07-05 | Cerestar Holding B.V. | Stabilized cyclodextrin complexes |
JP2003268005A (ja) * | 2002-03-14 | 2003-09-25 | Medorekkusu:Kk | 包接体の製造法 |
SI1622630T1 (sl) * | 2003-05-07 | 2012-12-31 | Osteologix A/S | Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti |
AU2004237437B2 (en) * | 2003-05-07 | 2011-01-20 | Osteologix A/S | Controlled release composition containing a strontium salt |
DK1534305T3 (da) | 2003-05-07 | 2007-02-05 | Osteologix As | Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte |
CN100374632C (zh) * | 2003-05-30 | 2008-03-12 | 三井化学株式会社 | 人造毛发用纤维 |
CA2531136A1 (en) * | 2003-07-04 | 2005-01-13 | Nycomed Danmark Aps | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
WO2005123130A2 (en) * | 2004-06-17 | 2005-12-29 | Osteologix A/S | Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
CN101018586B (zh) * | 2004-06-25 | 2014-08-27 | 莫克瓦洛Spf有限公司 | 含锶和维生素d的组合物及其用途 |
MXPA06015187A (es) * | 2004-06-25 | 2007-09-27 | Strontin Aps | Composiciones que comprenden estroncio y vitamina d y usos de las mismas. |
CA2603235A1 (en) * | 2005-03-28 | 2006-10-05 | Bioresponse, Llc | Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health |
DE102005017775A1 (de) * | 2005-04-13 | 2006-10-19 | Schering Ag | Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins |
US20070218111A1 (en) * | 2006-03-16 | 2007-09-20 | Western Holdings, Llc | Strontium compositions for bones |
CN1823764A (zh) * | 2006-03-27 | 2006-08-30 | 重庆医药工业研究院有限责任公司 | 一种含有雷奈酸锶和维生素d药物组合物 |
FR2899895B1 (fr) | 2006-04-12 | 2010-09-17 | Servier Lab | Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
KR100822133B1 (ko) * | 2006-11-06 | 2008-04-15 | 한미약품 주식회사 | 비타민 d 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제 |
-
2009
- 2009-11-27 FR FR0905706A patent/FR2953139B1/fr not_active Expired - Fee Related
-
2010
- 2010-11-11 MA MA33348A patent/MA32363B1/fr unknown
- 2010-11-15 SG SG201008356-6A patent/SG171542A1/en unknown
- 2010-11-16 IL IL209348A patent/IL209348A0/en unknown
- 2010-11-17 CL CL2010001260A patent/CL2010001260A1/es unknown
- 2010-11-17 ZA ZA2010/08230A patent/ZA201008230B/en unknown
- 2010-11-18 AU AU2010241527A patent/AU2010241527B2/en not_active Ceased
- 2010-11-18 UY UY0001033039A patent/UY33039A/es unknown
- 2010-11-18 MX MX2010012566A patent/MX2010012566A/es not_active Application Discontinuation
- 2010-11-19 CO CO10145569A patent/CO6280058A1/es not_active Application Discontinuation
- 2010-11-19 MY MYPI2010005459A patent/MY158261A/en unknown
- 2010-11-19 PE PE2010001074A patent/PE20110407A1/es not_active Application Discontinuation
- 2010-11-22 EC EC2010010622A patent/ECSP10010622A/es unknown
- 2010-11-23 CA CA2723119A patent/CA2723119C/fr not_active Expired - Fee Related
- 2010-11-23 US US12/927,733 patent/US20110130370A1/en not_active Abandoned
- 2010-11-24 SV SV2010003744A patent/SV2010003744A/es unknown
- 2010-11-24 CN CN2010105599459A patent/CN102078620A/zh active Pending
- 2010-11-24 NZ NZ589513A patent/NZ589513A/en not_active IP Right Cessation
- 2010-11-24 UA UAA201014025A patent/UA105766C2/uk unknown
- 2010-11-25 CU CU20100230A patent/CU20100230A7/es unknown
- 2010-11-25 AR ARP100104358A patent/AR079160A1/es not_active Application Discontinuation
- 2010-11-25 BR BRPI1004685-2A patent/BRPI1004685A2/pt not_active IP Right Cessation
- 2010-11-25 GE GEAP201012014A patent/GEP20135734B/en unknown
- 2010-11-26 WO PCT/FR2010/000787 patent/WO2011064474A1/fr active Application Filing
- 2010-11-26 TW TW099141091A patent/TW201200136A/zh unknown
- 2010-11-26 KR KR1020100118714A patent/KR101278935B1/ko not_active IP Right Cessation
- 2010-11-26 HN HN2010002518A patent/HN2010002518A/es unknown
- 2010-11-26 JP JP2010263698A patent/JP2011111458A/ja active Pending
- 2010-11-26 EP EP10290628A patent/EP2335704A1/fr not_active Withdrawn
- 2010-11-26 EA EA201001710A patent/EA018460B1/ru not_active IP Right Cessation
- 2010-12-01 AP AP2010005490A patent/AP2010005490A0/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2010002518A (es) | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
DOP2015000012A (es) | Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso | |
UY33776A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
SV2011004019A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
GT200900095A (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas. | |
EA201200551A1 (ru) | Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
TR201905586T4 (tr) | Amorf dapagli̇flozi̇n i̇çeren formülasyonlar | |
HN2011003139A (es) | Antagonistas de trayectoria de erizo de ftalazina disustituida | |
HN2010001920A (es) | Dihidropirazolonas sustituidas como inhibidores de hif- propil-4-hidroxilasa | |
DOP2007000043A (es) | Derivados de cromanol sustituidos y su uso | |
UA107204C2 (uk) | Протигрибкова композиція, що містить грибковий організм pythium oligandrum | |
ECSP11011483A (es) | Piperidinas sustituidas | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
HN2011003102A (es) | Piperidinas sustituidas | |
BR112013020359B8 (pt) | Colágeno gelificável e meios para a sua provisão | |
DOP2011000211A (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas | |
CU20080122A7 (es) | Nuevos derivados de furopirimidina acíclicos sustituidos y su uso | |
CU23951B1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa |